1. Bilezikian JP, Mulder JE, Silverberg SJ: Hypercalcemic states: differential diagnosis and acute management. In: Disorders of Bone and Mineral Metabolism (Coe and Favus, eds) 2nd Edition, Lippincott, Williams & Wilkins, Philadelphia, PA (In Press), 2006.
2. Brossard J-H, Lepage R, Cardinal H, Roy L, Rousseau L, Dorias C, d’Amour P. Influence of glomerular filtration rate on non-(1-84) parathyroid hormone (PTH) detected by intact PTH assays. Clin chem. 2000;46:697-703.
3. D’Amour P, Brossard J-H, Rousseau L. et al. Structure of non-(1-84) fragments secreted by parathyroid glands in primary and secondary hyperparathyroidism. Kidney Int. 2005;68:998-1007.
4. Bilezikian JP, Silverberg SJ, Rubin M, Potts, Jr. JT: Asymptomatic primary hyperparathyroidism: present management and future options. IN: Clinical Cases in Bone and Mineral Metabolism 3:132-140, 2006.
5. Gao P, Scheibel S, D’Amour P, John M, Rao S, Schmidt-Gayk H, Cantor T. Development of a novel immunoradiometric assy exclusively for biologically active whole parathyroid hormone 1-84: implications fo riprovement of accurate assessment of parathyroid function. J Bone Min Res 2001;16:605-614.
6. John MR, Goodman WG, Gao P, Cantor T, Salusky IB, Juppner H. A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragements; implications for PTH measurement in renal failure. J Clin Endocrinol Metab. 1999;84:4287-4290.
7. Silverberg SJ, Brown I, LoGerfo P, Gao P, Cantor T, Bilezikian JP: Clinical utility of an immunoradiometric assay for whole PTH (1-84) in primary hyperparathyroidism. J Clin Endocrinol Metab 88:4725-4730, 2003.
8. Wesseling K, Coburn JW, Salusky IB. The renal osteodystrophies. In: DeGroot LJ, Jameson JL eds. Endocrinology, vol 2. 5th ed. Philadelphia: Elsevier Saunders;2005;1697-1718.
9. Hruska KA, Teitelbaum SL: Renal osteodystrophy. N Eng J Med 1995, 333:166-174.
10. Martin KJ, Slatopolsky E: The parathyroids in renal disease: pathophysiology. In: Bilezikian JP, Marcus R, Levine MA eds. The Parathyroids, 2nd edition, 2001. San Diego, Academic Press, 625-634 .
11. Falchetti A, Bale AE, Amorosi A, Bordi C, Cicchi P, Bandini S, Marx SJ, Brandi ML: Progression of uremic hyperparathyroidism involves allelic loss on chromosome 11. J Clin Endocrinol Metab 1993;76:139-144.
12. Arnold A, Brown MF, Urena P, Randall, RG, Sarfati E, Drueke TB: Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Investig 1995;95:2047-2053.
13. Silverberg SJ, Bilezikian JP: “Incipient” primary hyperparathyroidism: a “forme fruste” of an old disease. J Clin Endocrinol Metab 88:5348-5352, 2003.
14. Maruani G, Hertig A, Paillard M, Houillier P. Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. J Clin Endocrinol Metab 2003;88:4641–8.
15.Tordjman KM, Greenman Y, Osher E, Shenkerman G, Stern N. Characterization of normocalcemic primary hyperparathyroidism. Am J Med 2004;117:861–3.
16. Lundgren E, Hagstrom EG, Lundin J, Winnerback K, Roos J, Ljunghall S, et al. Primary hyperparathyroidism revisited in menopausal women with serum calcium in the upper normal range at population-based screening 8 years ago. World J Surg 2002;26:931–6.
17. Lundgren E, Rastad J, Thrufjell E, Akerstrom G, Ljunghall S. Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery 1997;121:287–94.
18. Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ: Normocalcemic primary hyperparathyroidism: further characterization and short term natural history. J Bone Min Res 21 (Suppl 1) S37, 2006.
19. Heath H III, Hodgson SF, Kennedy M: Primary hyperparathyroidism: incidence, morbidity and potential economic impact in a community. N Engl J Med 1980;302:189-193.
20. Cope O: The story of hyperparathyroidism at the Massachusetts General Hospital. N Engl J Med 1966;21(1):174-182.
21. Keating FR Jr, Cook EN: Recognition of primary hyperparathyroidism: analysis of 24 cases. J Am Med Assoc 1945;129:994-1002.
22. Melton LJ III: Epidemiology of primary hyperparathyroidism. J Bone Mineral Res 1991;6(Suppl 2):S25-S30.
23. Stenstrom G, Heedman P: Clinical findings in patients with hypercalcemia: a final investigation based on biochemical screening. Acta Med Scand 1974;195:473-477.
24. Rastad J, Lundgren E, Ljunghall S: Clinical presentation of primary hyperparathyroidism. In: The Parathyroids, 2nd Edition (Bilezikian JP, Marcus R, Levine MA, eds), Academic Press, San Diego, CA 2001;361-374.
25. Palmer M, Jacobsson G, Akerstrom G, Ljunghall S: Prevalence of hypercalcemia in a health survey: A 14-year follow-up study of serum calcium values. Eur J Clin Invest 1988;18:39-46.
26. Christensson T, Hellstrom K, Wengle B, Alveryd A, Wikland B: Prevalence of hypercalcemia in a health screening in Stockholm. Acta Med Scand 1976;200:131-137.
27. Akerstrom G, Rudberg C, Grimelius L, Bergstrom R, Johansson H, Ljunghall S, Rastad J: Histologic parathyroid abnormalities in an autopsy series. Hum Pathol 1986;17:520-527.
28. Lundgren E, Rastad J, Thurfjell E, Akerstrom G, Ljunghall S: Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery 1997;121:287-294.
29. Lundgren E: Primary hyperparathyroidism of postmenopausal females. Prospective case-control analysis on prevalence, clinical characteristics and treatment. Compr Sum Ups Fac Med 1999;820:1-51.
30. Lindstedt G, Nystrom E, Lundberg P-A, Johansson E, Eggertsen R: Screening of an elderly population in primary care for primary hyperparathyroidism. Scand J Prim Health Care 1992;10:192-197.
31. Sorva A, Valvanne J, Tilvis RS: Serum ionized calcium and the prevalence of primary hyperparathyroidism in age cohorts of 75, 80 and 85 years. J Intern Med 1992;231:309-312.
32. Wermers RA, Khosla S, Atkinson EJ, Hodgson SF, O’Fallon WM, Melton III LJ: The rise and fall of primary hyperparathyroidism: A population-based study in Rochester, Minnesota, 1965-1992. Ann Intern Med 1997;126:433-440.
33. Cohen J, Gierlowski TC, Schneider AB: A prospective study of hyperparathyroidism in individuals exposed to radiation in childhood. JAMA 1990;264:581-584.
34. Bondeson AG, Bondeson L, Thompson NW: Hyperparathyroidism after treatment with radioactive iodine: not only a coincidence? Surgery 1989;106:1025-1027.
35. Brandi ML, Gagel RF, Angeli A et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Meta 2001;86:5658-5671.
36. Bilezikian JP, Brandi ML, Rubin M, Silverberg SJ: Primary hyperparathyroidism: new concepts in clinical, densitometric, and biochemical features. J Int Med, 257:6-17, 2005.
37. Simonds WF, James-Newton LA, Agarwal SK et al. Familial isolated hyperparathyroidism : clinical and genetic characteristics of 36 kindreds. Medicine (Baltimore) 2002;81:1-26.
38. Marx SJ, Simonds SF, Agarwal SK et al. Hyperparathyroidism in hereditary syndromes: special expressions and special managements. J Bone Min Res 2002;17(suppl 2): N37-43.
38a. Arnold A. Familial hyperparathyroid syndromes. In: Favus M, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 6th edition. Washington, DC: American Society for Bone and Mineral Research, 2006: 185-8.
38b. El-Hajj Fuleihan G, Arnold A. Parathyroid carcinoma. In: Rose BD, ed. UpToDate. Waltham, MA: UpToDate, Inc., 2007..
39. Brown EM. Four parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. J Clin Endocrinol Metab 1983;56:572-581
40. Gittes RF, Radde IC. Experimental model for hyperparathyroidism: effect of excessive numbers of transplanted isologous parathyroid glands. J Urol 1996;95:595-603 41. Parfitt M, Parathyroid growth: normal and abnormal. In: Bilezikian JP, Marcus R, Levine MA eds. The Parathyroids, 2nd edition, 2001. San Diego, Academic Press, 293-330.
41. Arnold A. Molecular basis of primary hyperparathyroidism. In: Bilezikian JP, Marcus R, Levine MA eds. The Parathyroids, 2nd edition, 2001. San Diego, Academic Press, 331-347.
41a. Mallya SM, Gallagher JJ, Wild YK, Kifor O, Costa-Guda J, Saucier K, Brown EM, Arnold A. Abnormal parathyroid cell proliferation precedes biochemical abnormalities in a mouse model of primary hyperparathyroidism. Mol Endocrinol 2005; 19:2603-9..
42. Arnold A. et al. Molecular pathogenesis of primary hyperparathyroidism. J Bone Min Res 17 (suppl 2): N30-N36.
43. Arnold A, Kim HG, Gaz RD et al. Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma. J Clin Invest 1989;83:2034-2040.
44. Rosenberg CL, Kim HG, Shows TB et al. Rearrangement and overexpression of D11S287E, a candidate oncogene on chromosome 11q13 in benign parathyroid tumors. Oncogene 1991;6:449-453.
45. Motokura T, Bloom T, Kim HG et al. A novel cyclin encoded by a bc11-linked candidate oncogene. Nature 1991;350:512-515.
46. Hemmer S, Wasenius VM, Haglund C et al. Deletion of 11q23 and cyclin D1 overexpression are frequent aberrations in parathyroid adenomas. Am J Path 2001;158:1355-1362.
47. His ED, Zukerberg LR, Yang WI et al. Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study. J Clin Endocrinol Metab 1996;81:1736-1739.
48. Tominaa Y, Tsuzuki T, Uchinda K et al. Expression of PRAD1/cyclin D1, retinoblastoma gene products, and Ki67 in parathyroid hyperplasia caused by chronic renal failure versus primary adenoma. Kidney Int 1999;55:1375-1383.
49. Vasef MA, Brynes R?K, Sturm M et al. Expression of cyclin D1 in parathyroid carcinomas, adenomas, and hyperplasias: a paraffin immunohistochemical study. Mod Pathol 1999;12:412-416.
50. Chandrasekharappa SC, Guru SC, Manickam P et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997;276:404-407.
51. European consortium on MEN1. identification of the multiple endocrine neoplasia type 1 (MEN1) gene. Hum Mol Genet 1997;6:1177-1183.
52. Carling T, Correa P, Hessman O et al. Parathyroid MEN1 gene mutations in relation to clinical characteristics of nonfamilial primary hyperparathyroidism. J Clin Endocrinol Metab 1998;83:2960-2963.
53. Farnebo F, The BT, Hytola S et al. Alterations of the MEN1 gene in sporadic parathyroid tumors. J Clin Endocrinol Metab 1998;83:2627-2630.
54. Shattuck TM et al. 2003. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Eng J Med 349:1722-1729.
55. Carpten JD et al. 2002. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet 32:676-680.
56. Krebs LJ et al. 2005. HRPT2 mutational analysis of typical sporadic parathyroid adenomas. J Clin Endocrinol Metab 90:5015-5017.
57. Howell VM, Cardinal JW, Richardson AL, Gimm O, Robinson BG, Marsh DJ.Rapid mutation screening for HRPT2 and MEN1 mutations associated with familial and sporadic primary hyperparathyroidism. J Mol Diagn. 2006 Nov;8(5):559-66.
58. Mizusawa N, Uchino S, Iwata T, Tsuyuguchi M, Suzuki Y, Mizukoshi T, Yamashita Y, Sakurai A, Suzuki S, Beniko M, Tahara H, Fujisawa M, Kamata N, Fujisawa K, Yashiro T, Nagao D, Golam HM, Sano T, Noguchi S, Yoshimoto K.Genetic analyses in patients with familial isolated hyperparathyroidism and hyperparathyroidism-jaw tumour syndrome.Clin Endocrinol (Oxf). 2006 Jul;65(1):9-16.
59. Tahara H, Smith AP, Gas RD et al. Genomic localization of novel candidate tumor suppressor gene loci in human parathyroid adenomas. Cancer Res 1996;56:599-605.
60. Palanisamy N, Imanishi Y, Rao PH et al. Novel chromosomal abnormalities identified by comparative genomic hybridization in parathyroid adenomas. J Clin Endocrinol Metab 1998;83:1766-1770.
61. Farnebo F, Kytola S, The BT et al. Alternative genetic pathways in parathyroid tumorigenesis. J Clin Endocrinol Metab 1999;84:3775-3780.
62. Bjorklun P, Kerstrom G, Westin G. Activated beta-catenin in the novel human parathyroid tumor cell line sHPT-1.Biochem Biophys Res Commun. 2007 Jan 12;352(2):532-6. Epub 2006 Nov 20. PMID: 17126301 [PubMed - in process]
63.Verdonk CA, Edis AJ: Parathyroid "double adenomas": fact or fiction? Surgery 90:523-526, 1981.
64. Harness JK, Ramsburg Sr, Nishiyama RH, Thompson NW: Multiple adenomas of the parathyroids: do they exist? Arch Surg 114:468-474, 1979.
65. Attie JN, Bock G, Auguste L: Multiple parathyroid adenoomas: report of thirty-three cases. Surgery 108:1014-102, 1990.
66. Silverberg SJ, Bilezikian JP: Primary hyperparathyroidism. In: Principles and Practice of Endocrinology and Metabolism (Becker KL, ed) Lippincott-Willliams & Wilkins, Philadelphia, PA 2001;564-573.
67. Bilezikian JP: Nephrolithiasis in primary hyperparathyroidism. In: Kidney Stones: Medical and Surgical Treatment (Coe FL, Favus MJ, Pak CYC, Parks JH, Preminger GM, eds) Lippincott-Raven, Philadelphia, 1996;783-802.
68. Bilezikian JP, Silverberg SJ, Shane E, Parisien M, Dempster DW: Characterization and evaluation of asymptomatic primary hyperparathyroidism. J Bone Mineral Res 1991;6(Suppl I):585-589.
69. Silverberg SJ, Bilezikian JP: Primary hyperparathyroidism: Still evolving? J Bone Min Res 12:856-862, 1997.
70. Silverberg SJ, Shane E, DeLaCruz L, et al. Skeletal disease in primary hyperparathyroidism. J Bone Mineral Res 1989;4:283-291.
71. Miller PD, Bilezikian JP: Bone densitometry in asymptomatic primary hyperparathyroidism. J Bone Min Res 2002;17 (Suppl 2) N98-N102.
72. Bilezikian JP, Silverberg SJ: Clinical spectrum of primary hyperparathyroidism. Reviews in Endocrine & Metabolic Disorders 2000;1:237-245.
73. Bilezikian JP, Silverberg SJ: Management of asymptomatic primary hyperparathyroidism. N Eng J Med 2004;350:1746-1751.
74. Hock JM, Canalis JM, Raisz LG. Parathyroid hormone: anabolic and catabolic
on bone and interactions with growth factors. In Bilezikian, JP (ed.). The Parathyroids: Basic and Clinical Concepts. San Diego, Academic Press, 2001: 183-198.
75. Slovik DM, Rosenthal DI, Doppelt SH, Potts JT, Daly MA, Neer RM: Restoration of spinal bone in osteoporotic men by treatment with human PTH (1-34) and vitamin D. J Bone Mineral Res 1986;1:377-381.
76. Bilezikian JP, Rubin MR, Finkelstein J: Parathyroid hormone as an anabolic therapy for women and men. J Endocrinological Investigation 2005;28 (Suppl 7):41-49.
77. Rubin MR, Bilezikian JP: Parathyroid hormone as an anabolic therapy. Drugs, 2005;65:2481-2498.
78. Silverberg SJ, Locker FG, Bilezikian JP. Vertebral osteopenia: a new indication for surgery in primary hyperparathyroidism. J Clin Endocrinol Metab 1996;81: 4007-4012.
79. Parisien M, Silverberg SJ, Shane E, et al. The histormorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure. J Clin Endocrinol Metab 1990;70:930-938.
80. Parisien M, Silverberg SJ, Shane E, de la Cruz L, Lindsay R, Bilezikian JP and Dempster DW. The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone. J Clin Endocrinol Metab 1990;70: 930-938.
81. Dempster DW, Parisien M, Silverberg SJ, Liang X-G, Schnitzer M, Shen V, Shane E, Kimmel DB, Recker R, Lindsay R, Bilezikian JP. On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism. J Clin Endocrinol Metab 1999;84:1562-1566.
82. Parisien M, Cosman F, Mellish RWE, Schnitzer M, Nieves J, Silverberg SJ, Shane E, Kimmel K, Recker R, Bilezikian JP, Lindsay R, Dempster DW. Bone structure in postmenopausal hyperparathyroid, osteoporotic and normal women. J Bone Min Res 1995;10:1393-1399.
83. Parisien M, Mellish RWE, Silverberg SJ, Shane E, Lindsay R, Bilezikian JP, Dempster DW. Maintenance of cancellous bone connectivity in primary hyperparathyroidism: trabecular and strut analysis. J Bone and Min Res 1992;7:913-920.
84. Dauphine RT, Riggs BL, Scholz DA: Back pain and vertebral crush fractures: an unrecognized mode of presentation for primary hyperparathyroidism. Ann Intern Med 1975;83:365-367.
85. Khosla S, Melton LJ III, Wermers RA, Crowson CS, O’Fallon WM, Riggs BL: Primary hyperparathyroidism and the risk of fracture: a population based study. J Bone Min Res 1999;14:1700-1707.
86. RJ, Rao DS, Ellis B, Kleerekoper M, Parfitt AM: Mild asymptomatic primary hyperparathyroidism is not a risk factor for vertebral fractures. Ann Intern Med 1988;109:959-962.
87. Melton LJ III, Atkinson EJ, O’Fallon WM, Heath H III: Risk of age-related fractures in patients with primary hyperparathyroidism. Arch Intern Med 1992;152:2269-2273.
88. Kleerekoper M, Peterson E, Nelson D, et al. Identification of women at risk for developing postmenopausal osteoporosis with vertebral compression fractures: role of history and single photon absorptiometry. Bone Mineral 1989;7:171-186.
89. Johnson BE, Lucasey B, Robinson RG, Lukert BP: Contributing diagnoses in osteoporosis. Arch Intern Med 1989;149:1069-1072.
90. Seeman E and Delmas PD. Bone Quality—the material and structural basis of bone strength and fagility.N Eng J Med 2006;354:2250-2261.
91. Adami S, Braga V, Squaranti R, Rossini M, Gatti D, Zamberlan N. Bone measurements in asymptomatic primary hyperparathyroidism. Bone 1998;22:565-570
92. Chen Q, Kaji H, Iu M-F, Nomur R, Sowa H, Yamauchi M, Tsukamoto T, Sugimoto T, Chihara K. Effects of an excess and a deficiency of endogenous parathyroid hormone on volumetric bone mineral density and bone geometry determined by peripheral quantitative computed tomography in female subjects. J Clin Endocrinol Metab 2003;88:4655-4658.
93. Parfitt AM, Parathyroid hormone and periosteal bone expansion. J Bone Miner Res 2002;17:1741-1743.
94. Bilezikian JP. Bone strength in primary hyperparathyroidism. Osteoporosis Int. 2003;14(Suppl 5):5113-5117.
95. Silverberg SJ, Bilezikian JP: Primary hyperparathyroidism. IN: Endocrinology, Fifth Edition (DeGroot LJ and Jameson JL, eds) Saunders, Philadelphia, PA 2005:1533-1554
96. Klugman VA, Favus M, Pak CYC. Nephrolithiasis in primary hyperparathyroidism. In: Bilezikian JP, ed. The Parathyroids: Basic and Clinical Concepts, 2nd ed, New York: Academic Press. 2001: 437-450.
96a. Scillitani A, Guarnieri V, Battista C et al. Primary hyperparathyroidism and the presence of kidney stones are associated with different haplotypes of the calcium-sensing receptor. J Clin Endocrinol Metab 2007;92:277-283.
97 Procopio M, Borretta G. Derangement of glucose metabolism in hyperparathyroidism. J Endocrinol Invest 2003;11:17-35.
98. Taylor WH, Khaeeli AA. Coincident diabetes mellitus and primary hyperparathyroidism. Diabetes Metab Res Rev 2001;17:175-180.
99. Procopio M, Magro G, Cesario F, Piovesan A, Pia A, Molineri N, Borretta G. The oral glucose tolerance test reveals a high frequency of both impaired glucose tolerance and undiagnosed Type 2 diabetes mellitus in primary hyperparathyroidism. Diabet Med 2002 19:958-961.
100. Marx S. Multiple Endocrine Neoplasia, type 1. In Bilezikan (ed) : The Parathyroids. New York, Academic Press. 2001, 535-584.
101. Norton JA, Cornelius MJ, Doppman JL et al. Effect of parathyroidectomy in patients with Zollinger-Ellison syndrome and MEN1: a prospective study. Surgery 1987;102:958-966.
102. Brandi ML, Gagel FR, Angeli A: Consensus guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86:5658-5671.
103. Sitges-Serra A, Alonso M, deLecea C, Gores PF, Sutherland DE: Pancreatitis and hyperparathyroidism. Br J Surg 1988;75:158-160.
104. Prinz RA, Aranha GV: The association of primary hyperparathyroidism and pancreatitis. Am Surg 1985;51:325-329.
105. Bess MA, Edis AJ, van Heerden JA: Hyperparathyroidism and pancreatitis. Chance or a causal association? JAMA 1980;243:246-247.
106. Patten BM, Bilezikian JP, Mallette LE et al. The neuromuscular disease of hyperparathyroidism. Ann Inter Med 1974;80:182-194.
107. Turken SA, Cafferty M, Silverberg SJ, et al. Neuromuscular involvement in mild, asymptomatic primary hyperparathyroidism. Am J Med 1989;87:553-557.
108. Joborn C, Rastad J, Stalberg E, Akerstrom G, Ljunghall S: Muscle function in patients with primary hyperparathyroidism. Muscle Nerve 1989;12:87-94.
109. Joborn C, Hetta J, Johansson H, et al. Psychiatric morbidity in primary hyperparathyroidism. World J Surg 1988;12:476-481.
110.Ljunghall S, Jakobsson S, Joborn C, Palmer M, Rastad J, Akerstrom G. 1991. Longitudinal studies of mild primary hyperparathyroidism. J Bone Mineral Res 1991;6(Suppl 2):S111-S116.
111. Silverberg SJ and Bilezikian JP. Clinical course of primary hyperparthyroidism. In: Bilezikian JP, Marcus R, Levine MA eds. The Parathyroids, 2nd edition, 2001. San Diego, Academic Press, 387-398.
112. Solomon BL, Schaaf M, Smallridge RC: Psychologic symptoms before and after parathyroid surgery. Am J Med 1994;96:101-106.
113. Roman S, Sosa JA. Psychiatric and cognitive aspects of primary hyperparathyroidism. Curr Opin Oncol 2007;19:1-5.
114. Harinarayan DV, Gupta N, Kochupillai N. Vitamin D status in primary hyperparathyroidism in India. Clin Endocrinol 1995;43:351-358.
115. Meng XW, Xing XP, Liu SZ, Chan ZW. The diagnosis of primary hyperparathyroidism-analysis of 134 cases. Acta Acad Med Sing 1994;16:115-122.
116. Luong KVQ, Nguyen LTH. Coexisting hyperthyroidism and hyperparathyroidism with vitamin D deficient osteomalacia in a Vietnamese immigrant. Endocr Pract 1996;2:250-254.
117. Bilezikian JP, Meng X, Shi Y, Silverberg SJ: Primary hyperparathyroidism in women: New York and Beijing (A Tale of Two Cities). Int'l J Fertility and Women’s Health 2000;45:158-165.
118 Mithal A, Bandeira F, Meng X, Silverberg S, Shi Y, Mishra SK, Griz L, Macedo G, Celdas G, Bandeira C, Bilezikian JP, Rao DS: Primary hyperparathyroidism in India, Brazil and China. In: The Parathyroids, 2nd Edition (Bilezikian JP, Marcus R, Levine MA, eds), Academic Press, San Diego, CA 2001,375-386.
119. Lumb GA, Stanbury SW. Parathyroid function in vitamin D deficiency in primary hyperparathyroidism. Am J Med 1974;54:833-839.
120. Silverberg SJ, Shane E, Dempster DW, Bilezikian JP. Vitamin D deficiency in primary hyperparathyroidism. Am J Med 1999;107:561-567.
121. Grey A, Lucas J, Horne A, Gamble G, Davidson JS, Reid I. Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D deficiency. J Clin Endocrinol Metab. 2005;90:2122-2126.
122. Tsien R. Calcium channels in the cardiovascular system. In Cardiac Electrophysiology, M Rosen et al eds). Futura, Mt. Kisco, New York. 1990: 75-90.
123. Hara M, Liu Y, Zhen L, Cohen IS, Yu H, Danilo P, Ogino K, Bilezikian JP, Rosen MR: The positive chronotropic actions of parathyroid hormone and parathyroid hormone-related peptide are due to increases in the current If, and the slope of the pacemaker potential. Circulation 1997;96:3704-3709.
124. Hedback G and Oden A. Increased risk of death from PHPT-an update. Eur J Clin Endocrinol 1998;28:271-276
125. Bitigen A, Tanalp AC, Kaynak E, Karavelioglu Y, Kirma C, Adas M, Yilmaz MB. Elastic properties of aorta in patients with primary hyperparathyroidism. Int J Clin Prac 2006;60:1572-1575.
126. Vestergaard P et al. Cardiovascular events before and after surgery for primary hyperparathyroidism. World J Surg 2003;27:216-222.
127. Nilsson IL et al. Endothelial vasodilatory function and blood pressure response to local and systemic hypercalcmia. Surgery 2001;130:986-990.
128. Nilsson IL et al. Endothelian vasodilatory dysfunction in primary hyperparathyroidism is reversed after parathyroidectomy. Surgery 1999;126:1049-1055.
129. Neuteufl TR. Impairment of endothelium-independent vasodilationin patients with hypercalcemia.Cardiovasc Res 1998;40:396-401.
130. Smith JC et al. Augmentation of central arterial pressure in primary hyperparathyroidism. J Clin Endocrinol Metab. 2000;85:3515-3519.
131. Rubin MR, Maurer MS, McMahon DJ, Bilezikian JP, Silverberg SJ al. Arterial stiffness in primary hyperparathyroidism. J Clin Endocrinol Metab 2005;90:3326-3330.
132. Wajngot A, Werner S, Granberg PO, Lindvall N: Occurrence of pituitary adenomas and other neoplastic diseases in primary hyperparathyroidism. Surg Gynecol Obstet 1980;151:401-403.
133. Farr HW, Fahey TJ, Jr. Nash AG, Farr CM: Primary hyperparathyroidism and cancer. Am J Surg 1973;126:539-543.
134. Attie JN, Vardhan R: Association of hyperparathyroidism with nonmedullary thyroid carcinoma: Review of 31 cases. Head Neck 1993;15:20-23.
135. Kambouris AA, Ansari MR, Talpos GT: Primary hyperparathyroidism and associated neoplasms. Henry Ford Med J 1987;35:207-210.
136. Wermers RA, Khosla S, Atkinson EJ, Grant CS, Hodgson SF, O’Fallon M, Melton LJ: Survival after the diagnosis of hyperparathyroidism. Am J Med 1998;104:115-122.
137. Palmer M, Adami H-O, Bergstrom R, Akerstroom G, Ljunghall S: Mortality after
surgery for primary hyperparathyroidism: A follow-up of 441 patients operated on from 1956 to 1979. Surgery 1987;102:1-7.
138. Hedback G, Oden A: Increased risk of death from primary hyperparathyroidism – an update. Eur J Clin Invest 1998;28:271-276.
139. Nilsson IL et al. Clinical presentation of PHPT in Europe-nationwide cohort analysis on mortality from nonmalignant causes. J Bone Miner Res 2002;17(Suppl2): N68-N74.
140. Walgenbach S, Hommel G, Junginger T: Outcome after surgery for primary hyperparathyroidism: Ten-year prospective follow-up study. World J Surg 2000;24:564-569.
141. Hedback G, Oden A, Tisell L-E: Parathyroid adenoma weight and the risk of death after treatment for primary hyperparathyroidism. Surgery 1995;117:134-139.
142. Hedback G, Oden A: Survival of patients operated on for primary hyperparathyroidism (letter). Surgery 1999;125:240-241.
143. Bilezikian JP, Brandi ML, Rubin M, Silverberg SJ: Primary hyperparathyroidism: new concepts in clinical, densitometric, and biochemical features. J Int Med, 2005;257:6-17.
144. Bilezikian JP, Silverberg SJ: Management of asymptomatic primary hyperparathyroidism. N Eng J Med 2004;350:1746-1751.
145. Bilezikian JP, Silverberg SJ: Primary hyperparathyroidism. In: Primer on the Metabolic Bone Diseases and Disorders of Calcium Metabolism, Sixth Edition (Favus M, editor) Am Soc Bone Min Research 2006;181-184.
146 Silverberg SJ, Bilezikian JP: The diagnosis and management of asymptomatic primary hyperparathyroidism. Nature Clinical Practice Endocrinology and Metabolism 2006;2:494-503.
147 Bilezikian JP, Silverberg SJ, Rubin M, Potts, Jr. JT: Asymptomatic primary hyperparathyroidism: present management and future options. IN: Clinical Cases in Bone and Mineral Metabolism 2006;3:132-140.
148. Consensus Development Conference Panel. Diagnosis and management of asymptomatic primary hyperparathyroidism: Consensus Development Conference Statement. Ann Intern Med 1991;114:593-597.
149. Bilezikian JP, Potts JT, El-Hajj Fuleihan G, Kleerekoper M, Neer R, Peacock M, Rastad J, Silverberg SJ, Udelsman R, Wells SA: Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Bone Min Res 2002;17 (Suppl 2) N2-N11; J Clin Endocrinol Metab 2002;87:5353-5361.
150. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP: A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. New Eng J Med 1999;341:1249 -1255.
151.. Silverberg SJ, Brown, I, Bilezikian JP: Age as a criterion for surgery in primary hyperparathyroidism. Am J Med 2002;113:681-684.
152. Silverberg SJ, McMahon D, Udesky J, Fleischer J, Shane E, Jacobs T, Siris E, Bilezikian JP: Natural history of untreated primary hyperparathyroidism: bone density after 15 years. J Bone Min Res 2006;21 (Suppl 1) S118.
153. Cockcroft D, Gault MD. Nephron 1976;16:31-41
154. Wells SA, DeBenedetti MK, Doherty GM. Surgery for recurrent or persistent hyperparathyroidism. J Bone Min Res 2002;17 (Suppl 2):N158-N162.
155. Wells SA Jr and Doherty GM. The surgical management of hyperparathyroidism. In: Bilezikian JP, Marcus R, Levine MA (eds) The Parathyroids, 2nd Edition, San Diego, Academic Press, 2001, 487-498
156. Ogilvie JB and Clark OH. Parathyroid surgery: we still need traditional and selective approaches. J Endocrinol Invest 2005;28:566-569.
157. Miccoli P. Parathyroid surgery; we only need a minimal surgical approach. J Endocrinolog Invest 2005;28:570-573.
158. Sosa JA, Udelsman R. Minimally invasive parathyroidectomy. Surg Oncol 2003;12:125-134.
159. Irvin GL III et al. Improved success rate in reoprative parathyroidectomy with intraoperative PTH assay. Ann Surg 1999;229:874-878.
160. Chen H et al. Intraoperative parathyroid hormone testing improves cure rates in patients undergoing minimally invasive parathyroidectomy. Surgery 2005;138:583-587.
161. Udelsman R. One hundred consecutive minimally invasive parathyroid explorations. Arch Surg 2000;31:1074-1078.
162. Udelsman R. Surgery in primary hyperparathyroidism: the patient without previous neck surgery. J Bone Min Res 2002;17(Suppl 2) N126-132..
163. Norton JA. Surgical management of hyperparathyroidism. In Endocrinology, 5th ed (DeGroot LJ and Jameson JL eds). WB Saunders, Philadelphia. 2006:1583-1594
164. Udelsman R. Six hundred fifty-six consecutive explorations for primary hyperparathyroidism. Ann Surg 2002;235:665-672.
165. Wells SA Jr et al. Long term-evaluation of patients with primary parathyroid hyperplasia managed by total parathyroidectomy and hetertopic autotransplantation. Ann Surg 1980;192:451-458.
166. Carling T. Udelsman R. Parathyroid surgery in familial hyperparathyroid disorders. J Inter Med 2005;257:27-37.
167. Cohen MS, Dilley WG, Wells SA, Moley JF, Doherty GM, Sicard GA, Skinner MA, Norton JA, DeBenedetti MK, Lairmore TC. Long-term functionality of cryopreserved parathyroid autograts: 1 13-year prospective analysis. Surgery 2005;138:1033-1040.
168. Alveryd A. Parathyroid glands in thyroid surgery. I. Anatomy of parathyroid glands. II. Postoperative hypoparathyroidism-identification and autotransplantion of parathyroid glands. Acta Chir Scand 1968;389:1-120.
169. Akerstrom G et al. Surgical anatomy of human parathyroid glands. Surgery 1984;95:14-21.
170. Wang CA. The anatomic basis of parathyroid surgery. Ann Surg 1976;183:271-275.
171. Rasmussen K, Larsen LP, Aryeschoug A, Theil Nielson J, Vestergaard P, Ronning H, Mosekilde , Christansen P. Predictive value of parathyroid sceintigraphy in preoperative evaluation of patients with primary hyperparathyroidism. Scand J Surg 2006;95:199-204.
172. Serra A, Bolasco P, Satta L, Nocolosi A., Uccheddu A, Piga M. Role of SPECT/CT in the preoperative assessment of hyperparathyroid patients. Radiol Med 2006;111:999-1008.
173. Freudenberg LS, Frilling A, Sheu SY, Gorges R. Optimizing preoperative imaging in primary hyperparathyroidism. Langenbecks Arch Surg 2006;391:551-556.
174. Alexander HR, Chen CC, Shawker T, Choyke P, Chang R, Marx S. The role of preoperative localization and intraoperative localization maneuvers including intraoperative PTH assay determination for patients with persistent or recurrent hyperparathyroidism. J Bone Min Res 2002;17(Suppl 2): N133-N140.
175. Doppman JL. Preoperative localization of parathyroid tissue in primary hyperparathyroidism. In: Bilezikian JP, Marcus R, Levine MA (eds) The Parathyroids, 2nd Edition, San Diego, Academic Press, 475-486, 2001
176. Ogilvie CM, Brown PL, Matson M, Dacie J, Rexnek RH, Britton K, Carpenter R, Beerney D, Drake WM, Jenkins PJ, Chew SL, Monson JP. Seletive parathyroid venous sampling in patients with complication hyperparathyroidism. Eur J Endocrinol 2006;155:213-221.
177. Roe SM, Burns RP, Graham LD, Brock WB, Russell WL. Cost-effectiveness of preoperative localization studies in primary hyperparathyroid disease. Ann Surg 1994;219:582-586.
178. Kaplan EL, Yoshiro T, Salti G. Primary hyperparathyroidism in the 1990s. Ann Surg 1992;215:300-317.
179. Udelsman R. Unilateral neck exploration under local or regional anesthesia. In : Gaganer M, Inaback III WB (eds) Minimally Invasive Endocrine Surgery, Lippincott, Williams and Wilkins, Philadelphia, 94-101, 2002.
180. Scholz DA, Purnell DC. Asymptomatic primary hyperparathyroidism. 10-year prospective study. Mayo Clin Proc 1981;56:473-478
181. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP: The natural history of treated and untreated asymptomatic primary hyperparathyroidism: a ten year prospective study. N Engl J Med 1999;341:1249-1255.
182. Silverberg SJ, McMahon D, Udesky J, Fleischer J, Shane E, Jacobs T, Siris E, Bilezikian JP: Natural history of untreated primary hyperparathyroidism: bone density after 15 years. J Bone Min Res 2006;21 (Suppl 1) S118.
183. Parfitt AM, Rao DS, Kleerekoper M. Asymptomatic primary hyperparathyroidism discovered by multichannel biochemical screening; clinical course and considerations bearing on the need for surgical intervention. J Bone Min Res 1991;6(suppl2):S97-S101.
184. Rao DS, Phillips ER, Divine GW, Talpos GB. Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 2004;89:5415-5422.
185. Parisien M, Dempster DW, Shane E, Bilezikian JP: Histomorphometric analysis of bone in primary hyperparathyroidism. In: The Parathyroids, 2nd Edition (Bilezikian JP, Marcus R, Levine M, eds) Academic Press, San Diego, CA 2001;423-436.
186. Seibel MJ, Gartenberg F, Silverberg SJ, et al. Urinary hydroxypyridinium crosslinks of collagen in primary hyperparathyroidism. J Clin Endocrinol Metab 1992;74:481-486.
187. Guo CY, Thomas W, Al-Dehaimi AW, Assiri AMA, Eastell R: Longitudinal changes in bone mineral density and bone turnover in women with primary hyperparathyroidism. J Clin Endocrinol Metab 1996;81:3487-3491.
188. Tanaka Y, Funahashi H, Imai T, Tominga Y, Takagi H: Parathyroid function and bone metabolic markers in primary and secondary hyperparathyroidism. Semin Surg Oncol 1997;13:125-133.
189. Minisola S, Romagnoli E, Scarnecchia L, et al. Serum CITP in patients with primary hyperparathyroidism: Studies in basal conditions and after parathyroid surgery. Eur J Endocrinol 1994;130:587-591.
190. Martin P, Bermann P, Sillet C: Partially reversible osteopenia after surgery for primary hyperparathyroidism. Arch Intern Med 1986;146:689-691.
191. Fuleihan GEH, Moore F Jr, LeBoff MS, Hurwitz S, Gundberg CM, Angell J, Scott J: Longitudinal changes in bone density in hyperparathyroidism. J Clin Densitometry 1999;2:153-162.
192. Almqvist EG, Becker C, Bondeson AG, Bondeson L, Svensson J. Early parathyroidectomy increases bone mineral density in patients with mild primary hyperparathyroidism: a prospective and randomized study. Surgery 2004;136(6):1281-8.
193. Kulak CAM, Bandeira C, Voss D, Sobieszczyk SM, Bandeira F, Silverberg SJ, Bilezikian JP. Marked improvement in bone mass after parathyroidectomy in osteitis fibros cystica.J Clin Endocrinol 1998;83:732-735.
194. Tritos NA, Hartzband P. Rapid improvement of osteoporosis following parathyroidectomy in a premenopausal woman with acute primary hyperparathyroidism.
195. Digregorio S. Hiperparatiroidismo primario; dramatico incremento de la masa ostea post paratiroidectomia. Diagn Osteol 1999;1:11-15.
196. Vestergaard P, Mosekilde L. Parathyroid surgery is associated with a decreased risk of hip and upper arm fractures in primary hyperparathyrioidism: a controlled cohort study. J Internal Med 2004;255:108-118.
197. Deaconson TF, Wilson SD, Lemann J: The effect of parathyroidectomy on the recurrence of nephrolithiasis. Surgery 1987;215:241-251.
198. Kaplan RA, Snyder WH, Stewart A, et al. Metabolic effects of parathyroidectomy in asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 1976;42:415-426.
199. Silverberg SJ. Non-classical target organs in primary hyperparathyroidism. J Bone Min Res 2003 (Suppl 2) N117-N125.
200. Burney RE, Jones KR, Christy B, Thompson NW. Health status improvement after surgical correction of primary hyperparathyroidism. Surgery 1999;125:608-614
201. Talpos GB, Bone HG, Kleerekooper M et al. Randomized trial of parathyroidectomy in mild asymptomatic primary hyperparathyroidism. Surgery 2000;128:1013-1020.
202. Brown GG, Preisman RC, Kleerekoper MD. Neurobehavioral symptoms in mild hyperparathyroidism: related to hypercalcemia but not improved by parathyroidectomy. Henry Ford Med J. 1987;35:211-215.
202. Roman SA, Sosa JA, Mayes L, Desmond E, Boudourakis L, Lin R, Snyder PJ, Holt E, Udelsman R. Parathyroidectomy improves neurocognitive deficits in patients with primary hyperparathyroidism. Surgery 2005;138:1121-1128.
203. Walker MD, Vardy SB, Inabnet WB, Brown I, McMahon DJ, Cosman F, Silverberg SJ. Neurocognitive changes in otherwise asymptomatic primary hyperparathyroidism. J Bone Miner Res 2006;21 (Suppl 1):S316
204. Brown GG, Preisman RC, Kleerekoper MD: Neurobehavioral symptoms in mild primary hyperparathyroidism: Related to hypercalcemia but not improved by parathyroidectomy. Henry Ford Med J 1987;35:211-215.
205. Cogan MG, Covey CM, Arieff AI, Wisniewski A, Clark OH: Central nervous system manifestations of hyperparathyroidism. Am J Med 1978;65:963-970.
206. Joborn C, Hetta J, Lind L, Rastad J, Akerstrom G, Ljunghall S: Self-rated psychiatric symptoms in patients operated on because of primary hyperparathyroidism and in patients with longstanding mild hypercalcemia. Surgery 1989;105:72-78.
207. Dotzenrath CM, Kaetsch AK, Pfingsten H, Cupisti K, Weyerbroach N, Vosburgh A, Verde PE, Ohmann C. Neuropsychiatric and cognitive changes after surgery in primary hyperparathyroidism. World J Surg 2006;30:680-685.
208. Bradley III EL, Wells JO: Primary hyperparathyroidism and hypertension. Am Surg 1983;49:569-570.
209. Rapado A: Arterial hypertension and primary hyperparathyroidism. Am J Nephrol 1986;6(Suppl I):49-50.
210. Dominiczak AF, Lyall F, Morton JJ, et al: Blood pressure, left ventricular mass and intracellular calcium in primary hyperparathyroidism. Clin Sci 1990;78:127-132.
211. Diamond TW, Botha JR, Wing J, Meyers AM, Kalk WJ: Parathyroid hypertension. A reversible disorder. Arch Intern Med 1986;146:1709-1712.
212. Broulik PD, Horky K, Pacovsky V: Blood pressure in patients with primary hyperparathyroidism before and after parathyroidectomy. Exp Clin Endocrinol 1985;86:346-352.
213. Ringe JD: Reversible hypertension in primary hyperparathyroidism pre- and postoperative blood pressur in 75 cases. Klin Wochenschr 1984;62:465-469.
214. Stefenelli T, Mayr H, Bergler-Klein J, Globits S, Woloszczuk W, Niederle B: Primary hyperparathyroidism: Incidence of cardiac abnormalities and partial reversibility after successful parathyroidectomy. Am J Med 1993;95:197-202.
215. Neunteufl T, Heher S, Prager G, Katzenschlager R, Abela C, Niederle B, Stefenelli T. Effects of successful parathyroidectomy on altered arterial reactivity in patients with hypercalcaemia: results of a 3-year follow-up study. Clin Endocrinol 2001;55:279-280.
216. Stock JL and Marcus R. Medical management of primary hyperparathyroidism. In: Bilezikian JP, Marcus R, Levine MA eds. The Parathyroids, 2nd edition, 2001. San Diego, Academic Press, 459-474.
217. Locker FG, Silverberg SJ, Bilezikian JP. Optimal dietary calcium intake in primary hyperparathyroidism. Am J Medicine 1997;102: 543-550
218. Marcus R, Madvig P, Crim M, Pont A, Kosek J: Conjugated estrogens in the treatment of postmenopausal women with hyperparathyroidism. Ann Intern Med 1984;100:633-640.
219. Selby PL, Peacock M: Ethinyl estradiol and norethinedrone in the treatment of primary hyperparathyroidism in postmenopausal women. N Engl J Med 1986;314:1481-1485.
220. Grey AB, Stapleton JP, Evans MC, Tatnell MA, Reid IR. Effect of hormone replacement therapy on BMD in post-menopausal women with primary hyperparathyroidism. Ann Int Med 1996;125: 360-368.
221. Writing group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women’s Health Initiative Randomized Controlled Trial. J Am Med Assoc 2002;228:321-333.
222. Marcus R. The role of estrogen and related compounds in the management of primary hyperparathyroidism. J Bone Miner Res 2002;17 (Suppl. 2): N146-N149.
223. Rubin MR, Lee K, McMahon DJ, Silverberg SJ. Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2003;88:1174-1178
224. Zanchetta JR and Bogado CE. Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism. J Bone Miner Res 2001;16:189-190.
225. Silverberg SJ, Bilezikian JP: Primary hyperparathyroidism. IN: Dynamics of Bone and Cartilage Metabolism (Seibel MJ, Robins SP, Bilezikian JP, eds) Elsevier Press, San Diego, CA, 2006;767-778.
226. Kaplan RA, Geho WB, Poindexter C, Haussler M, Dietz GW, Pak CYC. Metabolic effects of diphosphonate in primary hyperparathyroidism. J Clin Pharmacol. 1977;17:410-419.
227. Shane E, Baquiran DC, Bilezikian JP. Effects of dichloromethylene diphosphonate on serum and urinary calcium in primary hyperparathyroidism. Ann Int Med 1981;95:23-27.
228. Reasner CA, Stone MD, Hosking DJ, Ballah A, Mundy GR. Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate. J Clin Endocrinol Metab 1993;77:1067-1071.
229. Rossini M, Gatti D, Isaia G, Sartori L, Braga V, Adami S Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. 2001;16:113-119.
230. Hassani S, Braunstein GD, Seibel MJ, Brickman AS, Geola F, Pekay AE, Hershman JM. Alendronate therapy of primary hyperparathyroidism. The Endocrinologist. 2001;11:459-464.
231. Parker CR, Blackwell PJ, Fairbairn KJ, Hosking DJ. Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: J Clin Endocrinol Metab 2002;87:4482-4489.
232. Chow CC, Chan WB, Li JKY, Chan NN, Chan MH, Ko GTC, Lo KW, Cockram CS. Oral Alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2003;88:581-587.
233. Khan AA, Bilezikian JP, Kung AWC, Ahmed MM, Dubois SJ, Ho AYY, Schussheim D, Rubin MR, Shaikh AM, Silverberg SJ, Standish TI, Syed Z, Syed ZA: Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004;89:3319-3325.
234. Steffey ME, Fox J, Van Wagenen BC, DelMar EG, Balandrin MF, Nemeth EF. Calcimimetics: structurally and mechanistically novel compounds that inhibit hormone secretion from parathyroid cells. J Bone Mineral Res; 1993;8: s17.
235. Silverberg SJ, Marriott TB, Bone lll HG, Locker FG, Thys-Jacobs S, Dziem G, Sanguinetti ES, Bilezikian JP. Short term inhibition of parathyroid hormone secretion by a calcium receptor agonist in primary hyperparathyroidism. N Engl J Med 1997;307: 1506-1510, 1997.
236. Locatelli F, Pontoriero G, Limardo M, Tentori F. Cinacalcet hydrochloride: calcimimetic for the treatment of hyperparathyroidism. Expert Reve Endocrinol Metab 2006;1:167-179.
237. Shoback DM, Bilezikian JP, Turner SA, McCary LC, Guo MD, Peacock M: The calcimimetic AMG 073 normalizes serum calcium in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2003;88:5644-5649.
238. Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback DM: Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2005;90:135-141.
239. Peaock M, Scumpia S, Bolognese MA, Borofsky MA, Olson KA, McCary LC, Schwanauer LE, Shoback DM Long-term control of primary hyperparathyroidism with cinacalcet. J Bone Miner Res 2006;21 (Suppl 1) S38 (abstract)
240. Collins MT, Skarulis MC, Bilezikian JP, Silverberg SJ, Spiegel AM, Marx SJ: Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol & Metab 1998;83:1083-1088.
241. Rubin MR, Sliney J, Silverberg SJ, Bilezikian JP: Clinical course of 10 patients with inoperable parathyroid carcinoma treated with the calcimimetic cinacalcet HCI. J Bone Min Res 2004;19 (Suppl 1) S103.
242. Silverberg SJ, Faiman C, Bilezikian JP, Shoback DM, Rubin MR, Smallridge R, Schwanauer LE, Olson KA, Turner SA, Peacock M: Cinacalcet HCI effectively treats hypercalcemia in patients with parathyroid carcinoma. J Bone Min Res 2004;19 (Suppl 1) S103.
243. Silverberg SJ, Faiman C, Bilezikian JP, Shoback DM, Rubin MR, Smallridge R, Schwanauer LE, Olson KA, Klassen PS, Peacock M: Cinacalcet reduces hypercalcemia in patients with parathyroid carcinoma. J Bone Min Res 2006;21(Suppl 1): S440.